Based on this, a subsequent phase III trial (CHOICE-01) was conducted to evaluate whether toripalimab plus chemotherapy could provide better survival outcomes than chemotherapy in the first-line treatment of advanced NSCLC without EGFR/ALK driver mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.